Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1884 3
1885 1
1886 3
1887 5
1888 4
1890 2
1891 1
1892 1
1894 1
1903 2
1906 1
1909 1
1911 1
1912 1
1913 3
1915 1
1916 1
1917 2
1920 2
1930 1
1951 2
1953 4
1954 1
1955 2
1957 1
1958 1
1959 2
1960 2
1961 1
1964 1
1968 1
1969 1
1971 3
1972 5
1973 4
1974 4
1975 1
1976 1
1977 7
1978 4
1979 2
1980 3
1982 2
1983 1
1984 1
1986 4
1987 2
1988 4
1989 4
1990 4
1991 1
1993 3
1995 1
1996 8
1997 4
1998 5
1999 2
2000 4
2001 2
2002 4
2003 2
2004 4
2005 4
2006 5
2007 7
2008 1
2009 3
2010 4
2011 4
2012 4
2013 3
2014 4
2015 6
2016 3
2017 6
2018 5
2019 2
2020 3
2021 3
2022 6
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

219 results

Results by year

Filters applied: . Clear all
Page 1
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, Fischer HH, Jacot W, Conlin AK, Arce-Salinas C, Wapnir IL, Jackisch C, DiGiovanna MP, Fasching PA, Crown JP, Wülfing P, Shao Z, Rota Caremoli E, Wu H, Lam LH, Tesarowski D, Smitt M, Douthwaite H, Singel SM, Geyer CE Jr; KATHERINE Investigators. von Minckwitz G, et al. N Engl J Med. 2019 Feb 14;380(7):617-628. doi: 10.1056/NEJMoa1814017. Epub 2018 Dec 5. N Engl J Med. 2019. PMID: 30516102 Clinical Trial.
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.
von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, Bines J, Gelber RD, Piccart M, Baselga J; APHINITY Steering Committee and Investigators. von Minckwitz G, et al. N Engl J Med. 2017 Jul 13;377(2):122-131. doi: 10.1056/NEJMoa1703643. Epub 2017 Jun 5. N Engl J Med. 2017. PMID: 28581356 Free PMC article. Clinical Trial.
A phase 3 trial of bevacizumab in ovarian cancer.
Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, du Bois A, Sehouli J, Kimmig R, Stähle A, Collinson F, Essapen S, Gourley C, Lortholary A, Selle F, Mirza MR, Leminen A, Plante M, Stark D, Qian W, Parmar MK, Oza AM; ICON7 Investigators. Perren TJ, et al. N Engl J Med. 2011 Dec 29;365(26):2484-96. doi: 10.1056/NEJMoa1103799. N Engl J Med. 2011. PMID: 22204725 Free article. Clinical Trial.
Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE.
Mamounas EP, Untch M, Mano MS, Huang CS, Geyer CE Jr, von Minckwitz G, Wolmark N, Pivot X, Kuemmel S, DiGiovanna MP, Kaufman B, Kunz G, Conlin AK, Alcedo JC, Kuehn T, Wapnir I, Fontana A, Hackmann J, Polikoff J, Saghatchian M, Brufsky A, Yang Y, Zimovjanova M, Boulet T, Liu H, Tesarowski D, Lam LH, Song C, Smitt M, Loibl S. Mamounas EP, et al. Among authors: kunz g. Ann Oncol. 2021 Aug;32(8):1005-1014. doi: 10.1016/j.annonc.2021.04.011. Epub 2021 Apr 28. Ann Oncol. 2021. PMID: 33932503 Free article. Clinical Trial.
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.
Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Park-Simon TW, Rustin G, Joly F, Mirza MR, Plante M, Quinn M, Poveda A, Jayson GC, Stark D, Swart AM, Farrelly L, Kaplan R, Parmar MK, Perren TJ; ICON7 trial investigators. Oza AM, et al. Lancet Oncol. 2015 Aug;16(8):928-36. doi: 10.1016/S1470-2045(15)00086-8. Epub 2015 Jun 23. Lancet Oncol. 2015. PMID: 26115797 Free PMC article. Clinical Trial.
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, Normand SL, Braunwald E, Wiviott SD, Cohen DJ, Holmes DR Jr, Krucoff MW, Hermiller J, Dauerman HL, Simon DI, Kandzari DE, Garratt KN, Lee DP, Pow TK, Ver Lee P, Rinaldi MJ, Massaro JM; DAPT Study Investigators. Mauri L, et al. N Engl J Med. 2014 Dec 4;371(23):2155-66. doi: 10.1056/NEJMoa1409312. Epub 2014 Nov 16. N Engl J Med. 2014. PMID: 25399658 Free PMC article. Clinical Trial.
[Endometriosis and adenomyosis].
Leyendecker G, Kunz G. Leyendecker G, et al. Among authors: kunz g. Zentralbl Gynakol. 2005 Oct;127(5):288-94. doi: 10.1055/s-2005-836885. Zentralbl Gynakol. 2005. PMID: 16195971 Review. German.
Molecular genetics of antithrombin deficiency.
Lane DA, Kunz G, Olds RJ, Thein SL. Lane DA, et al. Among authors: kunz g. Blood Rev. 1996 Jun;10(2):59-74. doi: 10.1016/s0268-960x(96)90034-x. Blood Rev. 1996. PMID: 8813337 Review.
Adenomyosis and reproduction.
Leyendecker G, Kunz G, Kissler S, Wildt L. Leyendecker G, et al. Among authors: kunz g. Best Pract Res Clin Obstet Gynaecol. 2006 Aug;20(4):523-46. doi: 10.1016/j.bpobgyn.2006.01.008. Epub 2006 Mar 6. Best Pract Res Clin Obstet Gynaecol. 2006. PMID: 16520094 Review.
219 results